1[1]Dienstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med, 1995, 333(25): 1657-1661.
2[2]Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med, 1998, 339 (2): 61-68.
3[3]Richard Guan, Lai CL, Liaw YF, et al. Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol, 2001, 16 (Suppl): 60-61.
4[4]Farrell G. Hepatitis B e antigen seroconversion: effects of lamivudine alone or in combination with interferon alpha. J Med Virol, 2000, 61(3): 374-379.
5[5]Tassopoilos NC, Volpes R, Pastore G, et al. Lamivudine therapy in patients with anti-HBe positive chronic hepatitis B: end of treatment analysis. J Hepatol, 1998, 28 (Suppl 1 ): 43.
6[6]Schiff E, Karayalcin S, Grimm I, et al. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy. Hepatology, 1998, 28(Suppl): 338.
7[7]Fontana RJ, Lok AS. Lamivudine treatment in patients with decompensated hepatitis B cirrhosis: for whom and when? J Hepatology,2000, 33 (2): 329-332.
8[8]Yao FY, Bass N. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol, 2000, 33 (2): 301-307.
9[9]Yao FY, Terrault NA, Freise C, et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology,2001, 34 (2): 411-416.
10[10]Yao GB, WangBE, CuiZY, et al. Three years efficacy oflamivudine in the treatment of Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol, 2001, 16 (Suppl): 49.
